This study is in progress, not accepting new patients

Experimental Radiotracer Imaging Study for Cancer Patients

a study on Breast Cancer Colorectal Cancer Lung Cancer Malignant Neoplasm Pancreatic Cancer Colorectal Tumor Lung Tumor Pancreatic Neoplasms

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
study ends around
Principal Investigator
by Julie Sutcliffe (ucdavis)

Description

Summary

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Official Title

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Details

PRIMARY OBJECTIVES:

  1. To determine the safety, biodistribution and dosimetric properties of 18F-alphavbeta6-binding peptide (BP) in normal tissues and malignancies in cancer patients and correlate concordance with alphavbeta6 expression.

OUTLINE:

Patients receive 18F-alphavbeta6-BP intravenously (IV) and then undergo positron emission tomography (PET) scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.

After completion of study, patients are followed up for up to 6 months.

Keywords

Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma, Breast Neoplasms, Colorectal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, 18F-αvβ6-BP

Eligibility

You can join if…

Open to people ages 18 years and up

  • Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
  • Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
  • Will sign the Institutional Review Board (IRB)-approved consent form
  • Able to remain motionless for up to 30-60 minutes per scan

You CAN'T join if...

  • Creatinine > 2 x upper limit of normal
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal
  • Life expectancy < 3 months (mo)
  • Women who are pregnant or breast-feeding
  • Patients who cannot undergo PET/compute tomography (CT) scanning
  • Lack of availability for follow-up assessments
  • Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment

Location

  • University of California Davis Comprehensive Cancer Center
    Sacramento 5389489 California 5332921 95817 United States

Lead Scientist at University of California Health

  • Julie Sutcliffe (ucdavis)
    Professor, MED: Int Med Hematology/Oncology, School of Medicine. Authored (or co-authored) 67 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Julie L. Sutcliffe, Ph.D
ID
NCT03164486
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 27 study participants
Last Updated